Literature DB >> 16002743

Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia.

Raaj R Sankatsing1, Sigrid W Fouchier, Stefan de Haan, Barbara A Hutten, Eric de Groot, John J P Kastelein, Erik S G Stroes.   

Abstract

OBJECTIVE: Individuals with familial hypobetalipoproteinemia (FHBL) have been reported to be prone to fatty liver disease (FLD). Conversely, the profound reduction of low-density lipoprotein (LDL) cholesterol in this disorder might decrease cardiovascular risk. In the present study, we assessed hepatic steatosis as well as noninvasive surrogate markers for cardiovascular disease (CVD) in subjects with FHBL and in matched controls. METHODS AND
RESULTS: Hepatic steatosis was assessed by abdominal ultrasonography. Carotid intima-media thickness (IMT) and distal common carotid arterial wall stiffness as surrogate markers for CVD risk were measured using high-resolution B-mode ultrasonography. Whereas transaminase levels were only modestly elevated, both prevalence (54% versus 29%; P=0.01) and severity of steatosis were significantly higher in FHBL individuals compared with controls. Despite similar IMT measurements, arterial stiffness was significantly lower in FHBL (P=0.04) compared with controls. Additionally, the increase in arterial stiffness as seen in the presence of traditional risk factors was attenuated, suggesting that very low levels of apoB-containing lipoproteins can negate the adverse effects of other risk factors on the vasculature.
CONCLUSIONS: FHBL is characterized by an increased prevalence and severity of fatty liver disease. The observed decreased level of arterial wall stiffness, most pronounced in the presence of nonlipid risk factors, is indicative of cardiovascular protection in these subjects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16002743     DOI: 10.1161/01.ATV.0000176191.64314.07

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  25 in total

Review 1.  Genetics of lipid traits and relationship to coronary artery disease.

Authors:  Tanya E Keenan; Daniel J Rader
Journal:  Curr Cardiol Rep       Date:  2013-09       Impact factor: 2.931

2.  Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia?

Authors:  Stefano Ballestri; Amedeo Lonardo; Luisa Losi; Elisa Pellegrini; Marco Bertolotti; Paola Loria
Journal:  Intern Emerg Med       Date:  2008-07-17       Impact factor: 3.397

Review 3.  LDL-C-lowering therapy: current and future therapeutic targets.

Authors:  Maartje E Visser; Lily Jakulj; John J P Kastelein; Erik S G Stroes
Journal:  Curr Cardiol Rep       Date:  2008-11       Impact factor: 2.931

4.  A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia.

Authors:  Angelo B Cefalù; James P Pirruccello; Davide Noto; Stacey Gabriel; Vincenza Valenti; Namrata Gupta; Rossella Spina; Patrizia Tarugi; Sekar Kathiresan; Maurizio R Averna
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-30       Impact factor: 8.311

5.  Does inhibition of apolipoprotein B synthesis produce foie gras?

Authors:  Kenneth R Feingold
Journal:  J Lipid Res       Date:  2009-12-30       Impact factor: 5.922

6.  Low LDL-C levels are associated with risk of mortality in a Chinese cohort study.

Authors:  Jie-Ming Lu; Meng-Yin Wu; Zong-Ming Yang; Yao Zhu; Die Li; Zhe-Bin Yu; Peng Shen; Meng-Ling Tang; Ming-Juan Jin; Hong-Bo Lin; Li-Ming Shui; Kun Chen; Jian-Bing Wang
Journal:  Endocrine       Date:  2021-05-14       Impact factor: 3.633

7.  Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis.

Authors:  Ilenia Minicocci; Sara Santini; Vito Cantisani; Nathan Stitziel; Sekar Kathiresan; Juan Antonio Arroyo; Gertrudis Martí; Livia Pisciotta; Davide Noto; Angelo B Cefalù; Marianna Maranghi; Giancarlo Labbadia; Giovanni Pigna; Fabio Pannozzo; Fabrizio Ceci; Ester Ciociola; Stefano Bertolini; Sebastiano Calandra; Patrizia Tarugi; Maurizio Averna; Marcello Arca
Journal:  J Lipid Res       Date:  2013-09-20       Impact factor: 5.922

Review 8.  Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia.

Authors:  Tiffany Thomas; Henry Ginsberg
Journal:  Curr Atheroscler Rep       Date:  2010-01       Impact factor: 5.113

9.  Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia.

Authors:  Maartje E Visser; Fatima Akdim; Diane L Tribble; Aart J Nederveen; T Jesse Kwoh; John J P Kastelein; Mieke D Trip; Erik S G Stroes
Journal:  J Lipid Res       Date:  2009-12-14       Impact factor: 5.922

10.  Common and rare gene variants affecting plasma LDL cholesterol.

Authors:  John R Burnett; Amanda J Hooper
Journal:  Clin Biochem Rev       Date:  2008-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.